Ask AI
ProCE Banner Activity

MK-8591A-052 Week 96: Switch From BIC/FTC/TAF to DOR/ISL in People Living With Virologically Suppressed HIV

Conference Coverage
Slideset

Switching from BIC/FTC/TAF to DOR/ISL maintained a high and similar rate of virologic suppression vs continued BIC/FTC/TAF through 96 weeks without adversely affecting total lymphocyte or CD4+ cell counts and with a similar safety profile.

Released: February 25, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This program is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions